Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib for advanced, recurrent, or persistent cervical cancer
ChiCTR1800019587Phase 3Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anlotinib in Cervical Cancer (CC), sponsored by Shandong Cancer Hospital. Primary endpoints: Disease control rate and Objective response rate. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800019587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019587.